BiotechTube

Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Squamous Cell Carcinoma

Conditions

Esophageal Squamous Cell Carcinoma

Trial Timeline

Jul 30, 2025 → Jan 4, 2032

NCT ID
NCT06780111

About Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication

Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication is a phase 1/2 stage product being developed by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06780111. Target conditions include Esophageal Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06780111Phase 1/2Recruiting

Competing Products

20 competing products in Esophageal Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
41
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
52
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPhase 1
33
FamotidineAstellas PharmaPhase 2/3
65
ASP546CAstellas PharmaPhase 1/2
41
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
41
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
52
E3810 + E3810 + PlaceboEisaiPhase 3
77
Rabeprazole ER + RanitidineEisaiPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85